Studies in SSc lungs have found that SELE (and ICAM1) are found to be more highly expressed in diseased cells compared with healthy controls [79] and its inhibition could lead to an increase in successful therapeutic outcomes [78]. This evidence concerns the gene SELE and systemic sclerosis.